

# TABLE OF CONTENTS

September 8, 2008

No. 2105

## BUSINESS

- 1 Astellas Aims at Top Market Share in Japan  
- Overseas Sales Exceed 50% of Total Sales  
- Aiming at High Single-Digit Growth Rates in North America  
- Targeting Sales of 2.0 Bil. Euro in Europe  
- Aiming at 10th Place in Asia  
- No Generics of Prograf in US Despite Patent Expiration  
- Replacing Twice-a-Day Prograf with Once-a-Day Advagraf
- 3 **Stop Press**  
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
- 4 Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
- 4 Yamato Expects Profits from Generics Delivery Service in 3 Years  
- Generics' Ownership Retained by Makers
- 5 **BUSINESS NEWS IN BRIEF**  
- Otsuka Acquires IPP of Czech Republic  
- Sanofi-aventis Transfers Approval for Thymoglobulin to Genzyme Japan  
- IPEC Signs Contract with UMN for New Influenza Vaccine Manufacturing Facilities  
- Baxter: Granisetron for IV drip Infusion in Bag

## REGULATORY

- 6 16 Products (11 APIs) Recommended for NHI Price Listing  
- Peak Sales to Exceed ¥10 Bil. for 2 Products  
- 3 Products Excluded from DPC Payment System
- 8 CDFS Committee Recommends Conditional Approval of Thalidomide
- 9 Thalidomide Safety Control Criteria Discussed by Study Group
- 9 Committee Recommends Approval of Generic Vancomycin from Mylan
- 10 *Koroshō* to Demand ¥33.2 Bil. to Develop Drugs, Med. Devices  
- PFSB's Budget Request Up Due to Safety Measures, Anti-Flu Stockpiling  
- HPB Doubles Budget to Secure Doctors  
- ¥4.8 Bil. Earmarked for Anti-Dementia Measures  
- ¥16.2 Bil. for Anti-Cancer Measures
- 12 METI Demands ¥609.3 Bil. to Promote Science & Technology  
- MEXT Earmarks ¥86.1 Bil. for Life Science Research

## 12 Stop Press

- PM Yasuo Fukuda Steps Down

## R&D

- 14 CGI to Stop PIII Trial on Prostate Cancer Vaccine Licensed to Takeda
- 14 Takeda Suspends Development of Hematide for Chemotherapy-Induced Cancerous Anemia
- 15 Recommending *Hp* Eradication in All Infected Persons: JSHR  
- Gov't Should Urgently Take Effective Preventive Measures: Prof. Asaka
- 16 4 Healthcare Clusters to Focus on 4 Fields
- 16 **R&D NEWS IN BRIEF**  
- PIII Study of Nexavar as Adjuvant Therapy in Liver Cancer Initiated: Bayer, Onyx  
- J-Pharma to Accelerate Development of Anticancer Drugs  
- Agrex, Cronova to Cooperate More Closely in CRO Business  
- Epadel Inhibits Coronary Events in Hyperlipidemics: Mochida

## MEDICAL DEVICES

- 17 Vascular Embolization Set for AVM Recommended for Approval
- 18 BD Enters Market for Cytodiagnostic Systems for Cervical Cancer
- 18 Terumo's DuraHeart Implanted in 1st Patient in US
- 18 Use of CyberKnife II to Treat Tumors in Trunk of the Body Approved: Accuray

## SELF-MEDICATION

- 19 Seven APIs Recommended for Switching to OTC Status  
- RiUP Containing Minoxidil at 5% Recommended for Approval

## MEDICAL FACILITIES & NURSING CARE

- 20 A Case of Diagnosis and Treatment of Effort Angina in Japan: Part 1: Prologue
- 22 Draft Nat'l Medical Expenditure Optimization Plan Announced  
- JMA, JPA Opposes *Koroshō*'s Plan
- 22 Takara Bio to Start Cancer Cell Immunotherapy in Kyoto Clinic
- 23 Prevent Recurrence of Stroke: Prof. Hasegawa
- 23 **TOPICS**  
- Society to Prevent Uterocervical Cancer Inaugurated